Payment overview · 2025
General Payments
$243.12
15 reported records · 6 companies
Healthcare provider profile · identity verified
Derek J Ferrie, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MITCHELL, SD · NPI 1013962919
Verified facts
What the public records show
CMS Open Payments records show Derek J Ferrie, MD received $243.12 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.00 | 27.6% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $53.71 | 22.1% | 3 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $42.30 | 17.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.30 | 14.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.28 | 12.9% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.53 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.12 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $53.71 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.13 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $51.13 | 3 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $42.30 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.30 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $31.28 | 2 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 280 | 60 |
| Omeprazole | Omeprazole | 269 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 54 |
| Losartan Potassium | Losartan Potassium | 239 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 48 |
| Furosemide | Furosemide | 209 | 56 |
| Prednisone | Prednisone | 205 | 124 |
| Simvastatin | Simvastatin | 194 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 39 |
| Lisinopril | Lisinopril | 169 | 34 |
| Jantoven | Warfarin Sodium | 165 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 44 |
| Glimepiride | Glimepiride | 159 | 35 |
| Gabapentin | Gabapentin | 158 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 38 |
| Atenolol | Atenolol | 109 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 40 |
| Potassium Chloride | Potassium Chloride | 105 | 22 |
| Tramadol Hcl | Tramadol Hcl | 102 | 25 |
| Montelukast Sodium | Montelukast Sodium | 101 | 21 |
| Metformin Hcl Er | Metformin Hcl | 96 | 15 |
| Celecoxib | Celecoxib | 90 | 23 |
| Azithromycin | Azithromycin | 84 | 60 |
| Carvedilol | Carvedilol | 83 | 18 |
| Mirtazapine | Mirtazapine | 83 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 15 |
| Meloxicam | Meloxicam | 80 | 25 |
| Metformin Hcl | Metformin Hcl | 79 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 13 |
| Allopurinol | Allopurinol | 66 | 12 |
| Eliquis | Apixaban | 62 | 15 |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 56 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 53 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 11 |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Famotidine | Famotidine | 47 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Methocarbamol | Methocarbamol | 43 | 16 |
| Xarelto | Rivaroxaban | 42 | 11 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Ozempic | Semaglutide | 39 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 12 |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | 12 |
| Amoxicillin | Amoxicillin | 21 | 13 |
| Cephalexin | Cephalexin | 21 | 15 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 12 |
| Digoxin | Digoxin | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.12 · 15 records | PFIZER INC. | ABRYSVO, Azstarys, CAPVAXIVE, COMIRNATY, ENFLONSIA, GARDASIL 9, ImmunoCAP, JARDIANCE, Jornay PM, M-M-R II, NURTEC ODT, PREVNAR 20, ROTATEQ, VAXELIS, VAXNEUVANCE, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error